Dr. Anson Cheung, Professor of Surgery and Director of Cardiac Transplant at St. Paul's Hospital discusses transcatheter Tiara implantations
Neovasc Inc. (“Neovasc” or the “Company”), a developer of novel technologies to treat vascular disease, reported that the first results from early clinical experience with its Tiara™ prosthetic mitral valve were presented today at EuroPCR 2014, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
The two transcatheter Tiara implantations discussed at EuroPCR were conducted earlier this year under Special Access approvals at St. Paul's Hospital in Vancouver, Canada. Both resulted in well-functioning Tiara prosthetic mitral valves without paravalvular leak (PVL). Both procedures were straightforward and relatively short in duration; the time taken to implant the device in the first and second procedures was approximately 20 and 12 minutes respectively, with a total procedure time of about 1.5 hours for each case. There have been no Tiara device-related adverse events to date.